CVKD - Cadrenal Therapeutics Inc Total Debt to Capital
Cadrenal Therapeutics (CVKD) generates revenue from the supply of the innovative drug Tecarfarin to cardiology centers, where payments are provided by insurance companies. The firm's high pricing power is driven by patents and the low demand elasticity for a treatment that eliminates the risk of renal failure. The business is currently developing R&D projects to create a safe alternative for blood thinning. Market dynamics for the asset on GURU.Markets show that the total debt-to-equity ratio is 0.00.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_CVKD_-_Cadrenal-Therapeutics_-_All-Debt-to-Shareholders-Equity-Ratio "CVKD (Cadrenal Therapeutics) Total Debt to Capital history from 04/28/2023 to 10/31/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Cadrenal Therapeutics
This ratio reflects the proportion of borrowed funds to equity assets, allowing for an assessment of financial stability and the business's degree of dependence on external lending. By analyzing the financial leverage chart of Cadrenal Therapeutics (CVKD), an investor can track the liquidity risks of Cadrenal Therapeutics (CVKD), which is critical for a biotech firm during the costly clinical trial stage of an anticoagulant prior to entering phase two testing.